Comparison between EIL FPO and Parabolic Drugs IPO.
EIL FPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Parabolic Drugs IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of EIL FPO is up to ₹959.65 Cr whereas the issue size of the Parabolic Drugs IPO is up to ₹200.00 Cr. The final issue price of EIL FPO is ₹290.00 per share and of Parabolic Drugs IPO is ₹75.00 per share.
| EIL FPO | Parabolic Drugs IPO | |
|---|---|---|
| Face Value | ₹5 per share | ₹10 per share |
| Issue Price (Lower) | ₹270.00 per share | ₹75.00 per share |
| Issue Price (Upper) | ₹290.00 per share | ₹85.00 per share |
| Issue Price (Final) | ₹290.00 per share | ₹75.00 per share |
| Discount (Retail) | ₹14.50 per share | ₹0.00 per share |
| Discount (Employee) | ₹14.50 per share | ₹0.00 per share |
| Market Lot Size | 20 shares | 80 shares |
| Fresh Issue Size | 0 shares | 2,46,40,965 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹184.81 Cr |
| OFS Issue Size | 3,36,93,660 shares | 20,25,702 shares |
| OFS Issue Size (Amount) | up to ₹959.65 Cr | up to ₹15.19 Cr |
| Issue Size Total | 3,36,93,660 shares | 2,66,66,667 shares |
| Issue Size Total (Amount) | up to ₹959.65 Cr | up to ₹200.00 Cr |
EIL FPO opens on Jul 27, 2010, while Parabolic Drugs IPO opens on Jun 14, 2010. The closing date of EIL FPO and Parabolic Drugs IPO is Jul 30, 2010, and Jun 17, 2010, respectively.
| EIL FPO | Parabolic Drugs IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Jul 27, 2010 | Jun 14, 2010 |
| Issue Close | Jul 30, 2010 | Jun 17, 2010 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | Aug 12, 2010 | Jul 01, 2010 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
EIL FPO P/E ratio is , as compared to Parabolic Drugs IPO P/E ratio of .
| EIL FPO | Parabolic Drugs IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 90.4 | 63.21 | ||||
| Promoter Shareholding (Post-Issue) | 80.4 | 38.04 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹9771.16 Cr. | ₹464.19 Cr. | ||||
| ROE | ||||||
| ROCE | 6.21 | |||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW | 39.49 | 19.96 |
In the EIL FPO Retail Individual Investors (RII) are offered 1,15,43,581 shares while in Parabolic Drugs IPO retail investors are offered 1,15,43,581 shares. Qualified Institutional Buyers (QIB) are offered 1,64,90,830 shares in EIL FPO and 1,30,83,333 shares in Parabolic Drugs IPO.
| EIL FPO | Parabolic Drugs IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | ||
| QIB | 1,64,90,830 shares | 1,30,83,333 shares |
| NII | 49,47,249 shares | 39,25,000 shares |
| RII | 1,15,43,581 shares | 91,58,334 shares |
| Employee | 7,12,000 shares | 5,00,000 shares |
| Others | ||
| Total | 3,36,93,660 shares | 2,66,66,667 shares |
EIL FPO subscribed 0.00x in total, whereas Parabolic Drugs IPO subscribed 1.04x.
| EIL FPO | Parabolic Drugs IPO | |
|---|---|---|
| QIB (times) | 0.00x | 1.48x |
| NII (times) | 0.00x | 1.20x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 0.00x | 0.40x |
| Employee (times) | 0.00x | 0.11x |
| Other (times) | ||
| Total (times) | 0.00x | 1.04x |
